Organ-protective effects on the liver and kidney by minocycline in small piglets undergoing cardiopulonary bypass

Naunyn-Schmiedeberg's Archives of Pharmacology

Volumn 388, Issue 6, 2015, Pages 663-676

  Dhein, Stefan ^a   Grassl, Maria ^b   Gerdom, Maria ^a   Vollroth, Marcel ^a   Bakhtiary, Farhad ^a   Von Salisch, Sandy ^a   Krämer, Klaus ^a   Sobiraj, Axel ^a   Kostelka, Martin ^a   Mohr, Friedrich Wilhelm ^a   Salameh, Aida ^b  

^a UNIVERSITY OF LEIPZIG   (Germany)

^b UNIVERSITY HOSPITAL LEIPZIG   (Germany)

Author keywords

Antiapoptotic; Cardiopulmonary bypass; Extracorporeal circulation; Hepatic damage; Kidney; Liver; Minocycline; Nitrosative stress; Poly ADP ribose polymerase PARP; Renal impairment; Renoptrotection

Indexed keywords

ADENOSINE TRIPHOSPHATE; APOPTOSIS INDUCING FACTOR; CREATININE; HYPOXIA INDUCIBLE FACTOR 1ALPHA; LIVER ENZYME; MINOCYCLINE; POLY(ADENOSINE DIPHOSPHATE RIBOSE); TYROSINE; UREA; 3-NITROTYROSINE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PROTECTIVE AGENT;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BOWMAN CAPSULE; CARDIOPULMONARY BYPASS; CONGENITAL HEART MALFORMATION; CONTROLLED STUDY; CREATININE BLOOD LEVEL; HISTOLOGY; KIDNEY FAILURE; KIDNEY INJURY; KIDNEY TUBULE; LIVER INJURY; LIVER PROTECTION; NITROSYLATION; NONHUMAN; NUCLEAR LOCALIZATION SIGNAL; PIGLET; RENAL PROTECTION; UREA BLOOD LEVEL; ANALOGS AND DERIVATIVES; ANIMAL; DRUG EFFECTS; KIDNEY; LIVER; METABOLISM; PATHOLOGY; PIG;

ANIMALS; APOPTOSIS INDUCING FACTOR; CARDIOPULMONARY BYPASS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; KIDNEY; LIVER; MINOCYCLINE; POLY(ADP-RIBOSE) POLYMERASES; PROTECTIVE AGENTS; SWINE; TYROSINE;

EID: 84929945972     PISSN: 00281298     EISSN: 14321912     Source Type: Journal    
DOI: 10.1007/s00210-015-1115-4     Document Type: Article

References (40)

1. Alano CC, Kauppinen TM, Valls AV, Swanson RA (2006) Minocycline inhibits poly(ADP-ribose) polymerase-1 at nanomolar concentrations. Proc Natl Acad Sci U S A 103(25):9685-9690
2. An Y, Xiao YB (2007) Growth hormone prevents acute liver injury induced by cardiopulmonary bypass in a rat model. J Thorac Cardiovasc Surg 134:342-350
3. Andrási TB, Blázovics A, Szabó G, Vahl CF, Hagl S (2005) Poly(ADP-ribose) polymerase inhibitor PJ-34 reduces mesenteric vascular injury induced by experimental cardiopulmonary bypass with cardiac arrest. Am J Physiol Heart Circ Physiol 288(6):H2972-H2978
4. Ascione R, Talpahewa S, Rajakaruna C, Reeves BC, Lovell AT, Cohen A, Angelini GD (2006) Splanchnic organ injury during coronary surgery with or without cardiopulmonary bypass: a randomized, controlled trial. Ann Thorac Surg 81(1):97-103
5. Asimakopoulos G, Smith PL, Ratnatunga CP, Taylor KM (1999) Lung injury and acute respiratory distress syndrome after cardiopulmonary bypass. Ann Thorac Surg 68(3):1107-1115
6. Baskin E, Saygili A, Harmanci K, Agras PI, Özdemir FN, Mercan S, Tokel K, Saatci U (2005) Acute renal failure and mortality after open-heart surgery in infants. Ren Fail 27:557-560
7. Bellinger DC, Jonas RA, Rappaport LA, Wypij D, Wernovsky G, Kuban KC, Barnes PD, Holmes GL, Hickey PR, Strand RD (1995) Developmental and neurologic status of children after heart surgery with hypothermic circulatory arrest or low-flow cardiopulmonary bypass. N Engl J Med 332:549-555
8. Biró E, van den Goor JM, de Mol BA, Schaap MC, Ko LY, Sturk A, Hack CE, Nieuwland R (2011) Complement activation on the surface of cell-derived microparticles during cardiac surgery with cardiopulmonary bypass - is retransfusion of pericardial blood harmful? Perfusion 26:21-29
9. Cai DS, Jin BB, Pei L, Jin Z (2010) Protective effects of penehyclidine hydrochloride on liver injury in a rat cardiopulmonary bypass model. Eur J Anaesthesiol 27:824-828
10. Conlon PJ, Stafford-Smith M, White WD, Newman MF, King S, Winn MP, Landolfo K (1999) Acute renal failure following cardiac surgery. Nephrol Dial Transplant 14:1158-1162
11. Dhein S, Krause N, Ullmann C, Flister A, Lehmann S, Muth P, Walther T, Kostelka M, Mohr FW (2008) Ischemic and inflammatory lung impairment by extracorporeal circulation: effect of PARP-inhibition by INO1001. Pharmacol Res 58(5-6):332-339
12. du Plessis AJ (1999) Mechanisms of brain injury during infant cardiac surgery. Semin Pediatr Neurol 6(1):32-47
13. Esper SA, Subramaniam K, Tanaka KA (2014) Pathophysiology of cardiopulmonary bypass: current strategies for the prevention and treatment of anemia, coagulopathy, and organ dysfunction. Semin Cardiothorac Vasc Anesth 18:161-176
14. Fatokun AA, Dawson VL, Dawson TM (2014) Parthanatos: mitochondrial-linked mechanisms and therapeutic opportunities. Br J Pharmacol 171(8):2000-2016
15. Ingham E (1990) The effects of tetracyclines and erythromycin on complement activation in vitro. Acta Derm Venereol 70(6):531 - 534
16. Joza N, Pospisilik JA, Hangen E, Hanada T, Modjtahedi N, Penninger JM, Kroemer G (2009) AIF: not just an apoptosis-inducing factor. Ann N Y Acad Sci 1171:2-11
17. Kawahito K, Kobayashi E, Ohmori M, Harada K, Kitoh Y, Fujimura A, Fuse K (2000) Enhanced responsiveness of circulatory neutrophils after cardiopulmonary bypass: increased aggregability and superoxide producing capacity. Artif Organs 24:37-42
18. Kirklin JK, Westaby S, Blackstone EH, Kirklin JW, Chenoweth DE, Pacifico AD (1983) Complement and the damaging effects of cardiopulmonary bypass. J Thorac Cardiovasc Surg 86:845-857
19. Levy JH, Tanaka KA (2003) Inflammatory response to cardiopulmonary bypass. Ann Thorac Surg 75:715-720
20. Li S, Krawczeski CD, Zappitelli M, Devarajan P, Thiessen-Philbrook H, Coca SG, Kim RW, Parikh CR (2011) Incidence, risk factors, and outcome of acute kidney injury after pediatric cardiac surgery: a prospective multicenter study. Crit Care Med 39:1493-1499
21. Li Y, Li T, Qi H, Yuan F (2015) Minocycline protects against hepatic ischemia/reperfusion injury in a rat model. Biomed Rep 3(1):19-24
22. Pacher P, Szabó C (2007) Role of poly(ADP-ribose) polymerase 1 (PARP-1) in cardiovascular diseases: the therapeutic potential of PARP inhibitors. Cardiovasc Drug Rev 25(3):235-260
23. Plurad D, Martin M, Green D, Salim A, Inaba K, Belzberg H et al (2007) The decreasing incidence of late posttraumatic acute respiratory distress syndrome: the potential role of lung protective ventilation and conservative transfusion practice. J Trauma 63:1-7
24. Rosner MH, Portilla D, Okusa MD (2008) Cardiac surgery as a cause of acute kidney injury: pathogenesis and potential therapies. J Intensive Care Med 23:3-18
25. Ruvolo G, Speziale G, Greco E, Tritapepe L, Mollace V, Nistico G, Marino B (1995) Nitric oxide release during hypothermic versus normothermic cardiopulmonary bypass. Eur J Cardiothorac Surg 9:651-654
26. Sevrioukova IF (2011) Apoptosis-inducing factor: structure, function, and redox regulation. Antioxid Redox Signal 14(12):2545-2579
27. Stallwood MI, Grayson AD, Mills K, Scawn ND (2004) Acute renal failure in coronary artery bypass surgery: independent effect of cardiopulmonary bypass. Ann Thorac Surg 77:968-972
28. Stoney WS (2009) Evolution of cardiopulmonary bypass. Circulation 119:2844-2853
29. Szabó C (2005) Cardioprotective effects of poly(ADP-ribose) polymerase inhibition. Pharmacol Res 52:34-43
30. Szabó G, Soos P, Mandera S, Heger U, Flechtenmacher C, Bährle S et al (2004a) INO-1001 a novel poly(ADP-ribose) polymerase (PARP) inhibitor improves cardiac and pulmonary function after crystalloid cardioplegia and extracorporeal circulation. Shock 21:426-432
31. Szabó G, Seres L, Soós P, Flechtenmacher C, Zsengellér Z, Sack FU, Szabó C, Hagl S (2004b) Poly-ADP-ribose polymerase inhibition reduces mesenteric injury after cardiopulmonary bypass. Thorac Cardiovasc Surg 52(6):338-343
32. Talor JJ, Undar A (2011) Pediatric cardiopulmonary bypass: does perfusion mode matter? World J Pediatr Congenit Heart Surg 2:296-300
33. Tang ATM, Knott J, Nanson J, Hsu J, Haw MP, Ohri SK (2002) A prospective randomized study to evaluate the renoprotective action of beating heart coronary surgery in low risk patients. Eur J Cardiothorac Surg 22:118-123
34. Tao R, Kim SH, Honbo N, Karliner JS, Alano CC (2010) Minocycline protects cardiac myocytes against simulated ischemia-reperfusion injury by inhibiting poly(ADP-ribose) polymerase-1. J Cardiovasc Pharmacol 56(6):659-668
35. Tumlin J, Stacul F, Adam A, Becker CR, Davidson C, Lameire N, McCullough PA (2006) Pathophysiology of contrast-induced nephropathy. Am J Cardiol 98:14K-20K
36. Twal M, Kiefer P, Salameh A, Schnabel J, Ossmann S, von Salisch S, Krämer K, Sobiraj A, Kostelka M, Mohr FW, Dhein S (2013) Reno-protective effects of epigallocatechingallate in a small piglet model of extracorporeal circulation. Pharmacol Res 67(1):68-78
37. Virág L, Scott GS, Cuzzocrea S, Marmer D, Salzman AL, Szabó C (1998) Peroxynitrite-induced thymocyte apoptosis: the role of caspases and poly(ADP-ribose) synthetase (PARS) activation. Immunology 94:345-355
38. Volonté MG, Yuln G, Quiroga P, Consolini AE (2004) Development of an HPLC method for determination of metabolic compounds in myocyrdial tissue. J Pharm Biomed Anal 35:647-653
39. Weight SC, Furness PN, Nicholson ML (1998) New model of renal warm ischaemia-reperfusion injury for comparative functional, morphological and pathophysiological studies. Br J Surg 85:1669-1673
40. Yeh CH, Chen TP, Lee CH, Wu YC, Lin YM, Jing Lin P (2006) Inhibition of poly(adp-ribose) polymerase reduces cardiomyocytic apoptosis after global cardiac arrest under cardiopulmonary bypass. Shock 25(2):168-175